Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Shuyang YAO"'
Autor:
Ana M Pérez Gutiérrez, Shuyang Yao, Elena López-Isac, Blanca Gutiérrez, Jorge Cervilla, Esther Molina, Margarita Rivera, Patrick Sullivan
Publikováno v:
IBRO Neuroscience Reports, Vol 15, Iss , Pp S627- (2023)
Externí odkaz:
https://doaj.org/article/36ebc815d087463d8c9aafe3eaa1bb29
Autor:
Shuyang Yao, Funda Meric-Bernstam, David Hong, Filip Janku, Aung Naing, Sarina Anne Piha-Paul, Apostolia Maria Tsimberidou, Daniel Karp, Vivek Subbiah, Timothy Anthony Yap, Jordi Rodon Ahnert, Shubham Pant, Ecaterina E Ileana Dumbrava, Chetna Wathoo, Erick Campbell, Lihou Yu, Yuko Yamamura, Siqing Fu
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying CCNE1 amplification to determine the effect of this amplification for future therape
Externí odkaz:
https://doaj.org/article/a5b386ae4dfe4117b0a471663d796ae6
Autor:
Shuyang Yao, Filip Janku, Kimberly Koenig, Apostolia Maria Tsimberidou, Sarina Anne Piha‐Paul, Nai Shi, John Stewart, Amanda Johnston, John Bomalaski, Funda Meric‐Bernstam, Siqing Fu
Publikováno v:
Cancer Medicine, Vol 11, Iss 2, Pp 340-347 (2022)
Abstract Background Arginine depletion interferes with pyrimidine metabolism and DNA damage repair pathways. Preclinical data demonstrated that depletion of arginine by PEGylated arginine deiminase (ADI‐PEG 20) enhanced liposomal doxorubicin (PLD)
Externí odkaz:
https://doaj.org/article/995a8bbe88644f57a89f6a4d937e0443
Publikováno v:
BMC Women's Health, Vol 21, Iss 1, Pp 1-4 (2021)
Abstract Background Lung adenocarcinoma which invades ovaries is very rare. However, with the increase of long-survival female lung cancer, more patients will suffer ovarian metastasis. On grounds of the paucity of reported cases, the clinicopatholog
Externí odkaz:
https://doaj.org/article/b60335c4cdb048deb296182618e249cd
Publikováno v:
Chinese Journal of Lung Cancer, Vol 24, Iss 4, Pp 271-278 (2021)
Hyperprogressive disease (HPD) is a novel pattern of progression caused by immune checkpoint inhibitors (ICIs). It is characterized by a dramatic tumor surge and is associated with poor clinical outcomes. Up to now, the definition of HPD is still con
Externí odkaz:
https://doaj.org/article/4f53ab7d39a442e799209141722674da
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 165-171 (2020)
Vaccines have been used to fight and protect against infectious diseases for centuries. With the emergence of immunotherapy in cancer treatment, researchers began investigating vaccines that could be used against cancer, especially against tumors tha
Externí odkaz:
https://doaj.org/article/97954063819241e4a5892e2413b55ecc
Publikováno v:
Chinese Journal of Lung Cancer, Vol 23, Iss 8, Pp 685-688 (2020)
Immune checkpoint inhibitor (ICI) has been proven to be a major breakthrough in the treatment of various tumor types. Despite the favorable results in terms of oncological outcomes, these treatments have been associated with a variety of immune-relat
Externí odkaz:
https://doaj.org/article/412b45da30734551bedaa92554e3a79e
Publikováno v:
Thoracic Cancer, Vol 11, Iss 5, Pp 1265-1270 (2020)
Background IBM Watson for Oncology (WFO) provides physicians with evidence‐based treatment options. This study was designed to explore the concordance of the suggested therapeutic regimen for advanced non‐small cell lung (NSCLC) cancer patients b
Externí odkaz:
https://doaj.org/article/c7665365cc95408296a26007ebbcac46
Autor:
Shuyang YAO, Yi ZHANG
Publikováno v:
Chinese Journal of Lung Cancer, Vol 23, Iss 1, Pp 55-59 (2020)
Immune checkpoint inhibitor (ICI) has been proven to be a major breakthrough in patients with advanced non-small cell lung cancer. Up to now, neoadjuvant therapy using ICI are rare. However, in the context of cancer immunotherapy, neoadjuvant treatme
Externí odkaz:
https://doaj.org/article/d667f2c827664ada91860d108c82085a
Publikováno v:
Chinese Journal of Lung Cancer, Vol 20, Iss 11, Pp 737-740 (2017)
Background and objective The development of new treatments beyond first-line in metastatic non-small cell lung cancer (NSCLC) contributed to the increase in overall survival. Metronomic chemotherapy involves several mechanisms of anti-tumor with less
Externí odkaz:
https://doaj.org/article/dc8fd99326fb410591ab1c475d6e0e3b